drugset / Trial / NCT00783601

MK0524 Asthma POC Study (0524-008)(COMPLETED)

NCT00783601

Phase 2 Completed 130 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to demonstrate the benefit of MK0524 compared to placebo in patients with chronic asthma.

Timeline

Start
2004-10
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 10 mg
Subject laropiprant Small molecule 300 mg

Indications